Vaccines as Epidemic Insurance

Area of Science:

• Public Health
• Health Economics
• Vaccinology

Background:

• Global pandemics pose significant threats, necessitating proactive measures for vaccine development.
• The high costs and uncertain outcomes of vaccine research present financial risks to developers.
• Existing frameworks may not adequately incentivize timely vaccine availability during health crises.

Purpose of the Study:

• To examine the insurance-like properties of advance vaccine development for pandemics.
• To explore the potential of insurance mechanisms for vaccine developers and affected countries.
• To connect these concepts with current global efforts in pandemic preparedness.

Main Methods:

• Conceptual analysis of vaccine development as an insurance strategy.
• Economic modeling of costs and benefits associated with pre-pandemic vaccine portfolios.
• Review of existing government, industry, and philanthropic initiatives.

Main Results:

• Advance development of a vaccine portfolio exhibits insurance characteristics, balancing certain costs against potential catastrophic loss mitigation.
• Insurance can de-risk vaccine development, encouraging a broader range of preparedness.
• Insurance payouts can provide crucial support to nations impacted by unpredictable pandemics.

Conclusions:

• Viewing vaccine development through an insurance lens highlights its protective value against pandemic threats.
• Innovative insurance solutions are crucial for incentivizing timely vaccine R&D and ensuring equitable access.
• Policy alignment across government, industry, and philanthropy is essential for robust pandemic vaccine preparedness.